Pre-funded warrants (October 2025 public offering)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
VERU$2.11-2.11%
Veru Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$36.05M
Float & O/S:
Inst Own:
DilutionScan read 9 of VERU INC.'s SEC filings and found 3 warrant series, 2 ATM programs, 1 equity line, 3 shelf registrations and 1 completed offering on file for VERU. The latest dilution event on file is ATM sales on Jul 2, 2026. Analysis updated Sep 8, 2026.
Signal8 Summary
VERU
Clinical-stage biotech with tight cash runway
Snapshot
Veru is a clinical-stage biopharma that reported $0 in revenue for fiscal 2025 (down from $16.9M the prior year) and a $22.7M net loss, burning roughly $30M in cash from operations.
What's Happening Right Now
- : Fiscal Q3 net loss narrowed to $7.0M ($0.30/share) and cash rose to $23.9M, while the Phase 2b PLATEAU obesity trial finished enrolling 239 patients with interim results due Q1 2027.
- : Veru received a USPTO Notice of Allowance for a patent covering enobosarm combined with semaglutide for weight loss, giving protection until at least October 2044 once issued.
- : Veru announced full enrollment (about 200+ patients) in its Phase 2b PLATEAU study testing enobosarm plus semaglutide for weight loss in older adults, with final topline data expected Q4 2027.
Raise routes on file: active ATM + effective shelf · latest dilution event 124 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Jul 2, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Outstanding
Series A common stock warrants (October 2025 public offering)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Series B common stock warrants (October 2025 public offering)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
ATM program
Issued 2026
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
ATM program
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
Equity line
Issued 2023
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
S-3 shelf registration
Issued 2023
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Public offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your VERU trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
